Passa al contenuto
Merck

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Nature structural & molecular biology (2013-05-28)
Marie Pancera, Syed Shahzad-Ul-Hussan, Nicole A Doria-Rose, Jason S McLellan, Robert T Bailer, Kaifan Dai, Sandra Loesgen, Mark K Louder, Ryan P Staupe, Yongping Yang, Baoshan Zhang, Robert Parks, Joshua Eudailey, Krissey E Lloyd, Julie Blinn, S Munir Alam, Barton F Haynes, Mohammed N Amin, Lai-Xi Wang, Dennis R Burton, Wayne C Koff, Gary J Nabel, John R Mascola, Carole A Bewley, Peter D Kwong
ABSTRACT

HIV-1 uses a diverse N-linked-glycan shield to evade recognition by antibody. Select human antibodies, such as the clonally related PG9 and PG16, recognize glycopeptide epitopes in the HIV-1 V1-V2 region and penetrate this shield, but their ability to accommodate diverse glycans is unclear. Here we report the structure of antibody PG16 bound to a scaffolded V1-V2, showing an epitope comprising both high mannose-type and complex-type N-linked glycans. We combined structure, NMR and mutagenesis analyses to characterize glycan recognition by PG9 and PG16. Three PG16-specific residues, arginine, serine and histidine (RSH), were critical for binding sialic acid on complex-type glycans, and introduction of these residues into PG9 produced a chimeric antibody with enhanced HIV-1 neutralization. Although HIV-1-glycan diversity facilitates evasion, antibody somatic diversity can overcome this and can provide clues to guide the design of modified antibodies with enhanced neutralization.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Swainsonine, synthetic
Sigma-Aldrich
Swainsonine, from Metarrhizium anisopliae, ≥98% (TLC)